Eli Lilly vs Novo Nordisk: Fair Value & Quality
Both stocks run through our valuation models. Here is how Eli Lilly (LLY) and Novo Nordisk (NOVO-B) compare, as of Oct 30, 2026.
Head-to-head numbers
Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.
betterweakerfor reference, not scored
Novo Nordisk leads: 7 to 8 metric wins.
n/a = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
What the models say
How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.
▲above the price, more than 15% above ●close to the price, 85% to 115% of the price ▼below the price, more than 15% below
| Model family | Eli LillyPrice $1,418 | Novo NordiskPrice DKK 266 |
|---|---|---|
| DCF Models | ▼−78.1%below the price$311 | ▲+21.6%above the priceDKK 323 |
| Earnings-Based | ▼−81.8%below the price$257 | ●−3.2%close to the priceDKK 258 |
| Dividend Discount | ▼−90.4%below the price$136 | ●−6.1%close to the priceDKK 250 |
| Multiples | ▼−74.8%below the price$357 | ▲+30.1%above the priceDKK 346 |
| Asset-Based | ▼−99.3%below the price$10.62 | ▼−96.4%below the priceDKK 9.67 |
| Growth DCF | ▼−84.3%below the price$223 | ▼−23.4%below the priceDKK 204 |
| Economic Profit | ▼−81.2%below the price$267 | ●+2.0%close to the priceDKK 272 |
| Growth Earnings | ▼−73.5%below the price$375 | ▲+60.4%above the priceDKK 427 |
| Matching families | 8 of 8 | |
| Minimum | ▼−99.3%below the price$10.62 | ▼−96.4%below the priceDKK 9.67 |
| Maximum | ▼−73.5%below the price$375 | ▲+60.4%above the priceDKK 427 |
| Median | ▼−81.5%below the price$262 | ●−0.6%close to the priceDKK 265 |
| Geometric mean | ▼−87.6%below the price$176 | ▼−28.9%below the priceDKK 189 |
| Ahead family by family | 0 of 8 | 8 of 8 |
Minimum, maximum, median and geometric mean only use the families both stocks have (matching families: 8 of 8), so a family without a value on one side does not distort the comparison. Ahead in a family is the stock whose fair value there sits higher relative to its price. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.
Family by family: Novo Nordisk is ahead in 8 of 8 shared families, Eli Lilly in none.
Eli Lilly: 26 of 26 models see the stock below the current price.
Novo Nordisk: 15 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Eli Lilly · Health Care
Novo Nordisk · Health Care
Bottom line
As of Oct 30, 2026, Fair Value Calculator sees Novo Nordisk as the more attractively valued of the two: Eli Lilly trades at $1,418 versus a fair value of $750 (−47.1%), while Novo Nordisk trades at DKK 266 versus DKK 405 (+52.3%).
Eli Lilly has the higher quality score (67/100).
Open Novo Nordisk live analysis →More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.